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Abstract
PET IMAGING REVEALS REDUCED SYNAPTIC DENSITY IN PEOPLE WITH
WELL-CONTROLLED HIV INFECTION
Julian J. Weiss and Serena Spudich. Division of Neurological Infections & Global
Neurology, Department of Neurology, Yale University School of Medicine, New
Haven, CT

Background: Synaptic injury is a pathological hallmark of neurological
impairment in people living with HIV (PLWH), a common complication despite
viral suppression with antiretroviral therapy (ART). However, there are no
biomarkers sensitive to neurocognitive impairment in PLWH. Measurement of
synaptic density in living humans may allow better understanding of HIV
neuropathogenesis and provide a dynamic biomarker for therapeutic studies. We
applied novel synaptic vesical protein 2A (SV2A) positron emission tomographic
(PET) imaging to investigate synaptic density in the frontostriatalthalamic region
in PLWH and HIV-uninfected (HIV-) participants.
Methods: In this cross-sectional pilot study,13 older male PLWH on ART
underwent neurocognitive assessments, MRI, and PET scanning with the SV2A
ligand [11C]UCB-J with partial volume correction. SV2A binding potential (BPND)
in the frontostriatalthalamic circuit was compared to 13 age-matched HIVparticipants, and assessed with respect to neurocognitive performance in PLWH.
Results: PLWH had 14% lower frontostriatalthalamic SV2A synaptic density
compared to HIV- (PLWH: mean [SD], 3.93 [0.80]; HIV-: 4.59 [0.43]; P = .02,

effect size 1.02). Differences were observed in widespread additional regions in
exploratory analyses. Higher frontostriatalthalamic SV2A BPND associated with
better grooved pegboard performance, a measure of motor coordination, in
PLWH (r = 0.61, P = .03).
Conclusions: In this pilot study, SV2A PET imaging revealed reduced synaptic
density in older male PLWH on ART compared to HIV- both regionally in the
frontostriatalthalamic circuit and more globally. Larger studies controlling for
factors in addition to age are needed to determine whether differences are
attributable to HIV or comorbidities in PLWH. SV2A imaging is a promising
biomarker for studies of neuropathogenesis and therapeutic interventions in HIV.
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INTRODUCTION
HIV Infection and the Central Nervous System
Despite the widespread use of antiretroviral therapy (ART), 15 to 50% of
the approximately 38 million people living with HIV (PLWH) are affected by some
form of neurological impairment.2,3 This number has only grown as HIV
prevalence continues to increase, a long trend that has been occurring since the
introduction of ART, effectively transforming HIV into a chronic condition with life
expectancies of PLWH receiving ART approaching that of the general
population.4 However, a considerable gap remains in life expectancy, especially
comorbidity-free life expectancy.5,6 While HIV treatment and cure remain areas of
intense research in the field, the growing and aging population of PLWH has
spurred considerable investigation into chronic complications and outcomes in
PLWH.
Systemic inflammation and immune dysregulation have long been
recognized as having a central role in the course of HIV infection and AIDS.7-9
Notably, immune activation and inflammation persist, albeit generally to a lesser
degree, among PLWH on virally suppressive ART.10 These immunologic
abnormalities are thought to at least partially contribute to the disproportionate
prevalence of a wide variety of conditions, which span almost every organ
system, in this population.11-14 These include metabolic dysfunction and insulin
resistance,15 chronic kidney disease,16 cardiovascular disease,17 stroke,18 liver
disease,19 lung disease,20 cancers,21 bone disease,22 and cognitive dysfunction.23
Furthermore, PLWH have higher rates of comorbid conditions that likely
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contribute to the development of these chronic conditions, including opioid use
disorder (OUD), alcohol use disorder (AUD), mood disorders, and hepatitis C
infection, among others.24-26 Other important factors, such as greater rates of
incarceration and lower socioeconomic status, have also been studied in
association with disease development in PLWH.27-29
The landscape of HIV has changed significantly since the introduction of
ART, including from a neurology perspective. Early in the HIV pandemic, HIVassociated dementia (HAD) – originally termed AIDS dementia complex – was
recognized as an AIDS-defining illness that encompassed a range of symptoms
including (but not limited to) memory, motor, and behavioral dysfunction.30 The
prevalence of HAD among individuals with HIV was estimated to be
approximately 20-30% in the pre-ART era.31 Accordingly, at the time the vast
majority of neurological research on HIV focused on HIV encephalitis and HAD,
as well as opportunistic CNS infections and cancers, which themselves
contributed to the development of HAD and HIV encephalitis. However, since the
development and widespread use of ART, HAD and other AIDS-defining
illnesses are uncommon, as those with access to ART rarely progress to AIDS.
Conversely, shortly after the introduction of ART more subtle forms of
neurocognitive impairment – later termed HIV-associated neurocognitive
disorders (HAND)32 – were recognized in PLWH despite systemic virological
suppression.33 The persistence of these impairments, albeit in milder forms, was
initially thought to be at least partly due to poor blood-brain barrier penetration of
most commonly available ART agents at the time. However, cognitive
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dysfunction remains prevalent even with the advent of modern agents with
improved central nervous system (CNS) penetration – current treatment
regimens provide high rates of virological suppression both systemically and in
the CNS – and the declining use of agents with well-documented neurotoxicity
(i.e., efavirenz).34 Throughout the ever-evolving post-ART era, such cognitive
disorders have been increasingly reported, described, and studied in a diverse
range of populations, healthcare settings, and geographical regions. Although it
has been the subject of continually expanding research, many questions remain
about the evaluation and pathogenesis of these cognitive disorders.
Neuropathogenesis of HIV
As the terrain of the HIV pandemic has shifted over the last four decades,
our understanding of HIV’s effects on the CNS has evolved too. However,
despite the exponential advancement of the field since the introduction of ART,
the neuropathological basis of HAD and HIV encephalitis remains better
understood than the mild neurocognitive disorders more commonly encountered
today.
HAD and HIV Encephalitis: The Pre-ART Years
Early autopsy studies of patients with severe HAD revealed frequent
subcortical damage characterized by gliosis and macrophage infiltration.35
Contemporaneous studies isolated HIV from brain tissues and cerebrospinal fluid
(CSF), indicating that HIV directly caused the subcortical damage seen in
HAD.36-38 Interestingly though, associations between viral burden and
neurocognitive dysfunction were inconsistent. Multiple studies reported instances
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of high viral burden in neurologically intact donors as well as cases with low viral
burden in donors with HAD, implicating additional indirect factors in the
neuropathogenesis of HAD and HIV encephalitis.39 Shortly following these
pathological studies, neuroradiological studies using computed tomography (CT)
and magnetic resonance imaging (MRI) demonstrated cortical atrophy in patients
with HIV encephalitis, further characterizing the pathology.40,41 However, these
studies failed to detect the changes seen in pathologic studies (i.e., microglial
nodules with multinucleated giant cells). Notably, these early studies primarily
examined HAD and HIV encephalitis, the most severe neurologic manifestations
of HIV.
Landmark pathologic studies by Wiley and colleagues provided two key
additions to the understanding of HIV neuropathogenesis. First, they
demonstrated that reduced synaptic density, measured by concentration of
synaptophysin-immunoreactive presynaptic terminals, in the midfrontal cortex
was the primary pathology in donors with HIV encephalitis.42 Compared to the
brains of HIV donors without clinical neurological involvement, those of donors
with HIV encephalitis showed a statistically significant 25% decrease in
presynaptic terminals in the frontal cortex. Further though, reduced synaptic
density was also seen in the brains of HIV donors with mild neurocognitive
impairment compared to brains from donors without HIV.43,44 They also found a
direct association between the degree of impairment, as measured by
antemortem neuropsychological testing (NPT), and both decreased synaptic
density and dendritic complexity in the midfrontal cortex. Overall, these studies
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provided compelling evidence for synaptodendritic injury as a key pathological
component of mild neurocognitive dysfunction in PLWH with important
associations to the degree of clinical impairment.
Neurocognitive Dysfunction in PLWH: The Post-ART Era
In the years following the advent of ART, the incidence of HAD (and all
AIDS-defining illnesses) markedly decreased, while prevalence of more mild
neurocognitive disorders increased.45-48 Numerous studies have detailed the
changes that occur in the CNS during early untreated HIV infection, after
initiation of ART, and throughout long-term therapy. However, despite these wellstudied beneficial effects of ART on the CNS and the dramatically decreased
incidence of more severe HIV-related neurological disease, cognitive dysfunction
in PLWH persists despite effective ART and viral suppression, indicating that
ART does not provide complete protection against CNS disease in HIV.
Limited pathological studies of minor cognitive disorders in PLWH exist in
the post-ART era, though they provide important and logical insights. Bryant et
al. examined neuropsychological and postmortem neuropathologic data from
volunteers with untreated HIV, treated HIV with detectable plasma viral load, and
treated HIV with undetectable viral load. Greater synaptic density and dendritic
complexity were observed in the undetectable group, and lower synaptic density
was associated with increased likelihood of neurocognitive dysfunction.49 While
these results demonstrated a protective effect of ART on synapses and
dendrites, there was no comparison to an HIV-uninfected control group, so the
effects of HIV even among suppressed participants could not be determined.
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While these postmortem studies revealed synaptodendritic injury as a
hallmark neuropathological feature of neurocognitive impairment in PLWH, tools
to measure the specific loss of synaptic density have not been widely available,
particularly in living humans.42-44 Although regional cerebral atrophy, white matter
structural abnormalities, and disruptions in functional connectivity are common
features of CNS disease in HIV that suggest a loss of synaptic density, they are
highly variable and nonspecific.2,50-52 However, in the absence of methods to
directly measure synaptic density in PLWH, these and other surrogate markers
have been used to study neurocognitive impairment.
With advancements in MRI technology, more recent studies have turned
to this modality to measure brain atrophy in HIV. Structural MRI studies in PLWH
have found evidence for involvement of many brain regions, most consistently in
the frontal cortex, striatum, and thalamus; however, volume in these regions do
not clearly correlate with neurological dysfunction in PLWH on ART.53,54 As our
understanding of anatomical-functional correlates has evolved, with studies
demonstrating that distinct anatomic brain areas are linked as circuits to
accomplish complex tasks such as those tested in neuropsychological exams,
many began utilizing MRI to study functional connectivity in HIV. Disrupted
frontostriatal functional connectivity has been shown in such functional MRI
studies,55-57 consistent with early pathological studies demonstrating a particular
association of regional vulnerability to HIV in the dorsal striatum, mid frontal
cortex, thalamus, and hippocampus.43,58-60. While these regions have consistently
been implicated in studies using different methodologies, measures that are
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more specific and discriminatory than volumetric or functional analyses are
required to understand and intervene with the underlying substrate of neurologic
dysfunction in HIV.
Although the initial studies that identified synaptodendritic injury in HAD
and mild neurocognitive impairment in PLWH were published between 20 and 30
years ago, our understanding of the underlying pathogenic mechanisms resulting
in synaptodendritic injury in HIV remains limited. Proposed mechanisms (Figure
1) largely focus on inflammatory signaling due to immune cell proliferation,
especially resident microglial cells.61,62 Other likely contributors include direct
effects of HIV, such as viral replication and toxicity caused by viral proteins. 63,64
Host factors, including opiate and methamphetamine use, are also known to
have detrimental effects on both synapses and dendrites. 65,66

Figure 1: Schematic representation of putative mechanisms for synaptodendritic injury in
HIV.
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Advanced Imaging Techniques: PET Imaging in HIV
Recent advances in positron emission tomography (PET) imaging
technology have granted researchers additional tools for studying the effects of
HIV on the brain, complementing structural brain imaging studies.67 18Ffluorodeoxyglucose (FDG)-PET imaging studies have demonstrated cerebral
hypometabolism, particularly in frontal brain regions68,69 and the thalamus,70 in
PLWH. As persistent neuroinflammation plays a role in the pathophysiology of
neurocognitive dysfunction in HIV, measuring neuroinflammation in vivo has
been an area of great interest. PET imaging using radioligands targeting the
translocator protein (TSPO), a receptor expressed by microglia and astrocytes
that is upregulated during microglial activation, can effectively quantify the
amount of neuroinflammation in the brain.71 TSPO PET imaging has revealed
both global and regional elevations in TSPO expression in PLWH on ART, and
associations with poorer neurocognitive performance on domain-specific tasks.7274

However, findings have been mixed in these limited studies. One found no

significant differences in TSPO expression between PLWH and HIV-uninfected
controls, nor associations with any clinical HIV measures or plasma
biomarkers.75
The serotonergic76 and dopaminergic77 systems have also been targeted
in PET studies in PLWH, given the high rates of mood disorders78 and known
effects on the basal ganglia and resulting Parkinsonian-like symptomology,79
respectively. However, a very limited number of studies have been published in
humans. Histopathological studies have revealed beta-amyloid plaques and tau
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protein deposition in brains from patients with HIV.80,81 Despite the pathologic
evidence for amyloid and tau accumulation in HIV brains, PET imaging using
radioligands targeted against these substrates have surprisingly shown similar
levels of both amyloid and tau deposition when comparing PLWH to control
participants.82-84
Clinical Evaluation and Management of Cognitive Disorders in HIV
Defining cognitive dysfunction in PLWH has proven a challenge, resulting
in several research definitions of cognitive impairment in this population. 32,85-88
However, such definitions are often too inclusive and can lead to a diagnosis of
neurocognitive disorder in those who are clinically asymptomatic. Clinical
diagnosis is therefore a diagnosis of exclusion. Clinical evaluation relies on basic
labs and clinical MR imaging to exclude other conditions, as these tests are
generally normal in those with HIV-associated neurocognitive disorders. The
main defining feature is impaired performance on formal neuropsychiatric testing.
Unfortunately, in the ART era such cognitive testing is highly non-specific, as the
subtle deficits commonly seen in PLWH (i.e., executive function, memory) can
resemble those of other neurodegenerative disorders.89 Indeed, while multiple
test batteries have been created to assess HIV-associated neurocognitive
disorders, there remains no consensus on which to use.90
These current clinical diagnostic tools, including NPT and patient-reported
functional status, do not discriminate well between the various etiological bases
of neurological impairment in PLWH, including impairments due to aging or
comorbid conditions. Despite much research into the underlying
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neuropathogenesis of HIV and the development of neurological impairments,
there are currently no clear biological measures that define etiologic subtypes.91
This notable lack of biomarkers sensitive to neurocognitive impairment in HIV
impedes the ability to effectively understand its causes and develop targeted
treatments.
Considering the difficulty in distinguishing the etiology of neurocognitive
dysfunction in PLWH, management largely focuses on continued ART and
directed management of comorbidities (i.e., mood disorders, substance use
disorders, cardiovascular risk factors). Optimizing treatment of HIV is of particular
importance because of the well-known association between neurocognitive
impairments and both low CD4 T-cell count and higher viral load.92 In newly
diagnosed HIV, studies have found evidence that very early treatment initiation
may decrease neuroinflammation and confer some degree of protection against
the development of such impairments.93,94 Treatment intensification or a change
in ART agent should be considered for patients already on ART who have not
achieved viral suppression. Testing of other interventional treatments and agents
directed at neurocognitive dysfunction in PLWH has been limited by the lack of
biologically-based outcomes. Several adjunctive interventions have been
investigated, though these have generally shown limited and inconsistent effects
on cognitive performance.95,96
Measuring Synaptic Density in PLWH: SV2A PET Imaging
The recent development of the [11C]UCB-J radioligand has made
noninvasive in vivo estimates of synaptic density possible. [11C]UCB-J binds to
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the synaptic vesicle glycoprotein 2A (SV2A), which is ubiquitously present in
presynaptic nerve terminals throughout the brain (Figure 2).97 SV2A
concentration measured by high-resolution PET imaging effectively reflects the
density of nerve terminals, and therefore synaptic density. SV2A PET imaging
has been validated in both non-human primates and humans as a measure of in
vivo synaptic density, with prior studies showing a strong correlation with in vitro
synaptophysin concentration, the gold standard marker of synaptic density.98,99
Despite its recent development, SV2A PET imaging has already been used to
study numerous disease states, from classic neurodegenerative diseases with
well-studied anatomical correlates such as Alzheimer’s disease and Parkinson’s
disease, to psychiatric disorders including PTSD and depression.100-104

Figure 2: Schematic representation of SV2A location on presynaptic vesicles and
J binding.
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We capitalized on the availability of this new biomarker to apply the
understanding gained by pre-clinical and autopsy studies in a pilot study
investigating synaptic density in living humans with HIV on stable ART and
comparing to a cohort of matched HIV-uninfected participants. We chose the
frontostriatalthalamic circuit, an established functional circuit,105 as our primary
region of interest (ROI) based on neuropathological and MRI studies consistently
demonstrating regional synaptodendritic injury, brain atrophy, and functional
impairment.43,58-60 In addition, we hypothesized that loss of synaptic connections
in these regions affects neurocognitive function in PLWH despite ART.
Therefore, as a secondary analysis, we examined associations between synaptic
density in the frontostriatalthalamic circuit and neurocognitive assessments.

STATEMENT OF PURPOSE
The purpose of this study is to compare synaptic density, as measured by
SV2A binding, in participants with virologically suppressed HIV and HIVuninfected participants using novel [11C]UCB-J PET imaging. The hypothesis is
that synaptic density in the frontostriatalthalamic circuit, a functional circuit in the
brain that consistently demonstrates abnormalities in both neuropathological and
MRI studies of PLWH, would be lower in PLWH than in HIV-uninfected
participants. We also hypothesized that there would be a global reduction in
synaptic density in PLWH, so we also compared synaptic density in other brain
regions and identified those with reduced synaptic density in PLWH. Lastly, we
sought to identify any associations between synaptic density in the
frontostriatalthalamic circuit and performance on neurocognitive assessments.
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METHODS
Author Contributions
This author conceived the study analyses and performed all statistical
analyses, with Dr. Robert Pietrzak providing review of statistical methodology
and data analysis. The advisor conceived the study and study design. This
author was responsible for data collection, data generation, and data
management. These activities included downloading and transferring MRI scans,
performing FreeSurfer analysis on imaging data, selecting matched control
participants from the PET imaging repository, and normalizing NPT scores. The
author also shared responsibilities with other members of the study team in
performing NPT and accompanying participants to MRI and PET scans. The
author also created all schematic figures and graphs and worked with
collaborators to edit and modify the imaging figures. Collaborators participated in
study coordination, including participant recruitment, research procedures
including blood draws and lumbar punctures, neurocognitive assessments,
laboratory testing, and data management. A full list of coauthors is available in
the citation in the Additional Information section.
Study Participants
Male adults with HIV were recruited from the HIV Reservoirs and
Comorbidities (HARC) Study between May 2019 and February 2020. The HARC
Study is an established research protocol for neurological studies in PLWH,
individuals exposed to other infectious diseases that might impact the nervous
system, and HIV-uninfected comparison participants at Yale University. HIV-
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uninfected participants who had previously completed identical imaging studies in
other PET protocols at Yale University were selected from the Yale PET Center
database to achieve adequate sex- and age-matching, and, when possible,
race/ethnicity.106
All HIV participants underwent a screening evaluation to ensure eligibility.
HIV participants were required to have documented viral suppression (plasma
HIV RNA < 20 copies/mL) on ART for at least one year. Exclusion criteria
included active substance use disorder (SUD), current or past clinically
significant neurological illness, and any contraindications to participate in MRI,
PET, or lumbar puncture. Urine toxicology and standardized inventories for AUD
and SUD (World Health Organization’s Alcohol, Smoking, and Substance
Involvement Screening Test; Alcohol Use Disorders Identification Test) were
used to exclude participants with active SUD.107,108 Inclusion and exclusion
criteria were the same for the HIV-uninfected participants, except for those
criteria related to HIV infection and treatment. Blood and cerebrospinal fluid
(CSF) studies were collected as previously described for determination of CD4
and CD8 counts and HIV RNA quantification in the blood, and cell counts,
albumin, protein and HIV RNA in the CSF.109 Additional blood and CSF
specimens were collected and stored for future laboratory assessments,
including biomarkers of inflammation and immune activation. Where data were
not readily available in participants’ medical records, interviews were conducted
to record durations of HIV infection, durations of ART, current ART regimens,
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historical CD4 nadirs, and smoking histories. Demographic and HIV-specific
characteristics are shown in Table 1.
Ethics Statement and Human Subjects Research
The Yale University Human Investigation Committee, Institutional Review
Board (IRB), and the Radioactive Drug Research Committee approved the study.
Research was performed under IRB protocol IDs 1502015318 and 2000024620.
All participants provided written informed consent before inclusion in the study.
All data was maintained and stored using HIPAA compliant systems and storage.
MR Imaging
All participants underwent structural MRI scanning on a 3-Tesla Siemens
Prisma scanner. A three-dimensional magnetization prepared rapid acquisition
gradient echo T1-weighted sequence was used to exclude participants with
anatomical abnormalities and for coregistration with PET images to define ROIs.
Volumetric segmentation was performed with FreeSurfer 6.0 (Massachusetts
General Hospital) image analysis suite.110-112 FreeSurfer segmented the
individual whole head into 109 ROIs. FreeSurfer partially failed on two
participants due to abnormal intensity in the white matter, resulting in
inaccurately segmented ROIs; FreeSurfer failed in the caudate for one of these
participants and was redrawn manually for inclusion in the primary analysis.
Other mis-located ROIs from those participants were excluded from further
analyses as these ROIs were not part of the frontostriatalthalamic circuit, our
primary ROI.
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PET Imaging
Each participant received a [11C]UCB-J PET scan on the High Resolution
Research Tomograph (Siemens) for 60 minutes. Before the scan commenced,
an arterial line was placed so that the metabolite-corrected arterial input function
could be acquired. All PET imaging was performed according to previously
described procedures.113
PET Image Analysis
To control for the contributions of atrophy to the PET outcome measures,
Iterative Yang partial volume correction (PVC) was performed on dynamic PET
data using FreeSurfer ROIs (Figure 3).114 The Iterative Yang partial volume
algorithm corrects the original images frame-by-frame in a voxelwise manner
based on the spill-in and spill-out for each FreeSurfer ROI. The assumed point
spread function was Gaussian with 3.0 mm full-width-half-maximum. Bilateral
brain regions were derived from a weighted average of the corresponding
unilateral (i.e., left and right) regions. Regional volumes were calculated in
cortical ROIs delineated by FreeSurfer.
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Figure 3: Image processing and partial volume correction for atrophy of acquired PET
images.

The primary outcome measure was the binding potential (BPND), a
measure of specific binding only and the preferred outcome measure in PET
studies, calculated for each ROI using the centrum semiovale as the reference
region. The centrum semiovale has been validated as a reference region as it is
nearly devoid of SV2A, and total binding (VT) values in the centrum semiovale
were similar in both groups (HIV: 4.17 [0.99], 4.12 [0.55]; P = .86).98,115 The
arterial line failed in one HIV participant, so arterial data were not available for
this participant. Therefore, we applied the simplified reference tissue model 2
(SRTM2), which does not require arterial input data, to estimate regional BPND
values for all participants in our primary analysis.116 A global 𝑘2′ value (clearance
rate constant of the reference region) was used for SRTM2 (𝑘2′ = 0.027 min-1). To
ensure that the chosen method for calculating BPND did not affect results, the
one-tissue compartment (1TC) model, which requires arterial input data, was
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applied to compute the volume of distribution (VT); BPND values were derived
from VT (BPND = VT ROI / VT reference – 1), and all analyses were repeated using
these values. To generate group averaged PET images, the nonlinear
registration was used to transform BPND parametric images to automated
anatomical labeling template space.
The frontostriatalthalamic circuit value was defined as the average of the
BPND values for the frontal cortex, striatum, and thalamus. The striatum was
defined as the average values for the caudate and putamen. The composite
cerebral cortex region was defined as the average of the values for the frontal
cortex, occipital cortex, parietal cortex, temporal cortex, cingulate cortices, and
insula. The composite subcortical region was defined as the average of the
values for the thalamus, amygdala, hippocampus, caudate, putamen, pallidum,
and cerebellum cortex. The whole gray matter composite was defined as the
average of all regions included in the cortical and subcortical composites. For all
initial analyses, BPND for all composite regions (i.e., striatum,
frontostriatalthalamic circuit, cerebral cortex, subcortical regions, whole gray
matter) were calculated using an unweighted average of the constituent regions.
To ensure that the chosen method of calculating BPND for composite regions did
not affect results, BPND values for composite regions were also calculated using
volume-based weighted averages, and all analyses were repeated using these
values.
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Neuropsychological Assessment
HIV participants completed a 12 domain neuropsychological battery
developed to assess cognitive domains affected by HIV, as previously
described.109 It consisted of the timed gait test (functional mobility), Wide Range
Achievement Test 4 (WRAT-4) (composite test of reading, comprehension,
spelling, mathematics), Hopkins Verbal Learning Test – Revised (HVLT-R)
(verbal learning and memory), Trail Making Test Parts A (psychomotor speed)
and B (executive functioning), Grooved Pegboard test in the dominant and
nondominant hands (fine motor function), Wechsler Adult Intelligence Scale
(WAIS-III) (cognitive ability), Stroop tests (color reading, word reading, and
inference) (processing speed and attention), letter fluency tasks (verbal
functioning), category fluency tasks (verbal functioning), and finger tapping test in
the dominant and nondominant hands (motor functioning). Z-scores were
determined based on normative values from published studies, or the test
developers’ normative data, with participants matched for age and education,
and where possible, gender and race. Participants also completed the
NeuroMacro assessment, a standardized clinical exam for common neurological
features in PLWH.
Statistical Analysis
Data were reported as mean (standard deviation, SD) values for normally
distributed continuous variables, and median (interquartile range, IQR) for nonnormally distributed continuous variables. Group differences in SV2A-specific
binding (BPND) in the primary brain region (frontostriatalthalamic circuit) were
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assessed using a two-tailed, independent-samples t test with P < .05 as a
threshold for statistical significance. Multiple regression models were conducted
to evaluate the relationship between BPND and HIV status, adjusting for individual
potential confounders including age, education, and race, as well as for all three
covariates together. In a secondary exploratory analysis, a multivariate analysis
of variance was conducted to compare SV2A binding in multiple ROIs between
the two groups. The relationship between BPND and neurocognitive performance
in the HIV group was assessed using Pearson correlations. Associations
between BPND and demographic and clinical measures in the HIV group were
assessed using Pearson correlations for continuous variables and t test for
categorical variables. Statistical analyses and procedures were performed using
JMP (version 15; SAS),SPSS Statistics (version 26; IBM), and Prism (version
7.0; GraphPad) software.
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RESULTS
Study Participant Characteristics
Thirteen male adults with virologically suppressed HIV completed the
study. Comparison imaging data from thirteen male HIV-uninfected participants
were selected from the Yale PET Center database based on age and, when
possible, race/ethnicity. Demographic and HIV-specific characteristics are shown
in Table 1. HIV-uninfected participants included a significantly smaller proportion
of non-White participants (77% of the HIV group, 31% of the HIV-uninfected
group; P = .02 ) and were somewhat more highly educated (mean [SD] 13.4 [2.5]
years in HIV participants,15.1 [1.7] years of education in the HIV-uninfected
group; P = .06), but were well-matched on age (59.8 [5.1], 57.3 [6.8]; P = .29).
The HIV participants had well-controlled disease, with a median CD4 Tcell count of 689, and only two participants had a quantifiable viral load. Overall,
the HIV group had a long history of HIV infection, with a median of 23 years since
HIV diagnosis (range: 6-31 years). All but one of the participants had transitioned
from a protease inhibitor-based ART regimen to either an NNRTI or integrase
inhibitor-based regimen.
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Table 1: Demographics and Clinical Characteristics of Participants

Demographic characteristic
Male sex, No. (%)
Age, mean (SD), y
Non-white race, No. (%)
Hispanic, No. (%)
BMI, mean (SD), kg/m2
Education, mean (SD), yb
History of SUD, No. (%)
History of AUD, No. (%)
Smoking
Ever, No. (%)
Current, No. (%)
Former, No. (%)
HIV-specific characteristic
CD4+ T-cells, median (IQR), cells/μL
CD4+/CD8+ ratio, mean (SD)
CD4+ nadir, median (IQR), cells/μLc
Plasma HIV RNA <20 copies/mL, No. (%)
CSF HIV RNA <20 copies/mL, No. (%)d
CSF white blood cells, mean (SD), cells/μLd
CSF protein, mean (SD), mg/dLd
CSF:blood albumin ratio, mean (SD)d
Duration of HIV infection, median (IQR), y
Duration of ART, median (IQR), y
Current NRTI, No. (%)
Current NNRTI, No. (%)
Current integrase inhibitor, No. (%)
Current PI, No. (%)
Current pharmacokinetic enhancer, No. (%)

HIV
(n = 13)

HIVuninfected
participants
(n = 13)
P valuea

13 (100)
59.8 (5.1)
10 (77)
2 (15)
28.9 (5.5)
13.4 (2.5)
8 (62)
5 (38)

13 (100)
57.3 (6.8)
4 (31)
0 (0)
29.2 (3.1)
15.1 (1.7)
N/A
N/A

N/A
.29
.02
.14
.87
.06
N/A
N/A

9 (69)
5 (38)
4 (31)

N/A
N/A
N/A

N/A
N/A
N/A

689 (504, 865)
1.01 (0.44)
166 (83, 383)
11 (85)
9 (75)
3.8 (3.6)
41 (20)
5.8 (3.7)
23 (16, 28)
22 (12, 25)
13 (100)
4 (31)
8 (62)
1 (8)
2 (15)

Abbreviations: ART, antiretroviral therapy; AUD, alcohol use disorder; BMI, body mass index;
CSF, cerebrospinal fluid; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SUD, substance
use disorder.
P values are Student’s t test (continuous variables) or Χ2 test (categorical variables).
n = 11 for the HIV-uninfected participants.
c Nadir CD4 count was unavailable for 4 participants.
d One participant did not have a lumbar puncture.
a
b
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Group Differences in Synaptic Density in the Frontostriatalthalamic Circuit
HIV participants exhibited significantly lower synaptic density, as defined
by [11C]UCB-J SRTM2-derived BPND measurement, in the frontostriatalthalamic
circuit, our primary ROI, compared with HIV-uninfected participants. After partial
volume correction, frontostriatalthalamic circuit BPND was 14% lower in HIV
participants (3.93 [0.80], 4.59 [0.43]; P = .02) with a large effect size (Cohen’s d =
1.02) (Figure 4, Table 2).

Figure 4: Frontostriatalthalamic mean SV2A binding potential (BPND) after partial volume
correction by HIV status. Error bars represent 95% confidence intervals. Individual data points
are shown for all participants in each group.

This result was largely unchanged when using 1TC-derived BPND and/or
using a weighted average to calculate frontostriatalthalamic BPND (Tables 3-5).
The group differences remained significant in the frontostriatalthalamic region for
all derivations of BPND except the 1TC weighted average values, which
approached significance (4.79 [1.04], 5.46 [0.55]; P = .06). A significant group
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difference remained in the frontostriatalthalamic circuit after the addition of either
age (P = .03), education (P = .03), or race (P = .03) as a covariate, and effect
sizes remained large in magnitude (Cohen’s d range: 0.94-0.99). Group
differences by HIV status did not remain significant when adjusting for age,
education, and race together (P = .08) (Table 6). Although frontostriatalthalamic
synaptic density was lower in the HIV group, the volume of the circuit was similar
in both groups (Table 7).
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Table 2: SV2A PET Synaptic Density (BPND) in Brain Regions of Interest
(SRTM2 Unweighted Averages)
BPND
Mean (SD)
HIV-uninfected
participants
(n = 13)

Region of Interest
Primary region
Frontostriatalthalamic
4.59 (0.43)
Secondary regionsb
Whole gray
4.79 (0.54)
Cerebral cortex
5.86 (0.73)
Frontal cortex
6.08 (0.67)
Superior frontal gyrus
5.93 (0.67)
Paracentral lobule
4.98 (0.60)
Parietal cortex
6.77 (0.90)
Postcentral gyrus
6.02 (0.70)
Superior parietal lobule
6.65 (0.76)
Precuneus
6.69 (0.88)
Occipital cortex
6.04 (0.83)
Cuneus
6.40 (0.90)
Lingual gyrus
5.53 (0.78)
Temporal cortex
6.00 (0.79)
Parahippocampal gyrus
4.02 (0.56)
Temporal pole
4.69 (0.61)
Entorhinal
3.31 (0.45)
Cingulate
Anterior cingulate
6.41 (0.89)
Posterior cingulate
5.60 (0.75)
Isthmus cingulate
4.55 (0.68)
Insula
5.39 (0.68)
Subcortical regions
3.57 (0.34)
Thalamus
2.69 (0.25)
Amygdala
4.14 (0.41)
Hippocampus
2.90 (0.40)
Striatum
4.98 (0.50)
Putamen
5.66 (0.54)
Caudate
4.31 (0.55)
Pallidum
2.25 (0.32)
Cerebellum cortex
3.02 (0.41)
Abbreviation: BPND, binding potential.
a

HIV (n = 13)

% difference

Cohen’s d

P valuea

3.93 (0.80)

-14.3%

1.02

.02

4.13 (0.86)
4.98 (1.14)
5.22 (1.28)
4.95 (1.35)
4.13 (1.06)
5.54 (1.49)
4.85 (1.21)
5.19 (1.72)
5.36 (1.39)
4.94 (1.16)
5.14 (1.15)
4.44 (1.13)
5.30 (1.09)
3.39 (0.67)
3.93 (0.86)
3.19 (0.61)

-13.7%
-14.9%
-14.2%
-16.5%
-16.9%
-18.1%
-19.4%
-21.9%
-19.8%
-18.3%
-19.6%
-19.8%
-11.7%
-15.7%
-16.1%
-3.5%

.03
.03
.045
.03
.02
.02
.007
.01
.009
.01
.005
.009
.07
.02
.02
.59

5.48 (1.39)
4.82 (1.08)
3.94 (0.91)
4.64 (0.97)
3.15 (0.55)
2.33 (0.38)
3.79 (0.62)
2.52 (0.47)
4.24 (0.80)
5.08 (0.94)
3.39 (0.80)
2.32 (0.44)
2.64 (0.63)

-14.6%
-14.1%
-13.5%
-13.8%
-11.5%
-13.3%
-8.3%
-12.8%
-15.0%
-10.3%
-21.2%
+2.9%
-12.5%

.053
.04
.06
.03
.03
.01
.11
.04
.01
.07
.003
.67
.08

P values are for 2-tailed, unpaired t tests.
These analyses were exploratory and not corrected for multiple comparisons due to the
preliminary nature of the study.
b
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Table 3: SV2A PET Synaptic Density (BPND) in Brain Regions of Interest
(SRTM2 Weighted Averages)
BPND
Mean (SD)
HIV-uninfected
participants
(n = 13)

Region of Interest
Primary region
Frontostriatalthalamicb
5.72 (0.59)
Secondary regionsc
Whole grayb
5.40 (0.63)
Cerebral cortexb
6.19 (0.75)
Frontal cortex
6.08 (0.67)
Superior frontal gyrus
5.93 (0.67)
Paracentral lobule
4.98 (0.60)
Parietal cortex
6.77 (0.90)
Postcentral gyrus
6.02 (0.70)
Superior parietal lobule
6.65 (0.76)
Precuneus
6.69 (0.88)
Occipital cortex
6.04 (0.83)
Cuneus
6.40 (0.90)
Lingual gyrus
5.53 (0.78)
Temporal cortex
6.00 (0.79)
Parahippocampal gyrus
4.02 (0.56)
Temporal pole
4.69 (0.61)
Entorhinal
3.31 (0.45)
Cingulate
Anterior cingulate
6.41 (0.89)
Posterior cingulate
5.60 (0.75)
Isthmus cingulate
4.55 (0.68)
Insula
5.39 (0.68)
Subcortical regionsb
3.21 (0.36)
Thalamus
2.69 (0.25)
Amygdala
4.14 (0.41)
Hippocampus
2.90 (0.40)
Striatumb
5.08 (0.52)
Putamen
5.66 (0.54)
Caudate
4.31 (0.55)
Pallidum
2.25 (0.32)
Cerebellum cortex
3.02 (0.41)
Abbreviation: BPND, binding potential.
a

Cohen’s d

% difference

4.91 (1.15)

-14.1%

4.61 (1.06)
5.26 (1.24)
5.22 (1.28)
4.95 (1.35)
4.13 (1.06)
5.54 (1.49)
4.85 (1.21)
5.19 (1.72)
5.36 (1.39)
4.94 (1.16)
5.14 (1.15)
4.44 (1.13)
5.30 (1.09)
3.39 (0.67)
3.93 (0.86)
3.19 (0.61)

-14.6%
-15.1%
-14.2%
-16.5%
-16.9%
-18.1%
-19.4%
-21.9%
-19.8%
-18.3%
-19.6%
-19.8%
-11.7%
-15.7%
-16.1%
-3.5%

.03
.03
.045
.03
.02
.02
.007
.01
.009
.01
.005
.009
.07
.02
.02
.59

5.48 (1.39)
4.82 (1.08)
3.94 (0.91)
4.64 (0.97)
2.81 (0.60)
2.33 (0.38)
3.79 (0.62)
2.52 (0.47)
4.33 (0.84)
5.08 (0.94)
3.39 (0.80)
2.32 (0.44)
2.64 (0.63)

-14.6%
-14.1%
-13.5%
-13.8%
-12.5%
-13.3%
-8.3%
-12.8%
-14.8%
-10.3%
-21.2%
+2.9%
-12.5%

.053
.04
.06
.03
.051
.01
.11
.04
.01
.07
.003
.67
.08

0.88

P values are for 2-tailed, unpaired t tests.
BPND for these composite regions were calculated using a volume-based weighted average of
the constituent regions.
c These analyses were exploratory and not corrected for multiple comparisons due to the
preliminary nature of the study.
b

P valuea

HIV (n = 13)

.04
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Table 4: SV2A PET Synaptic Density (BPND) in Brain Regions of Interest (1TC
Unweighted Averages)
BPND
Mean (SD)
HIV-uninfected
participants
(n = 13)

Region of Interest
Primary region
Frontostriatalthalamic
4.38 (0.41)
Secondary regionsb
Whole grayc
4.56 (0.52)
Cortical regionsc
5.58 (0.70)
Frontal cortex
5.81 (0.61)
Superior frontal gyrus
5.65 (0.61)
Paracentral lobule
4.79 (0.61)
Parietal cortexd
6.45 (0.87)
Postcentral gyrus
5.77 (0.70)
Superior parietal lobuled
6.34 (0.80)
Precuneusd
6.38 (0.84)
Occipital cortexd
5.79 (0.83)
Cuneusd
6.14 (0.92)
Lingual gyrus
5.30 (0.82)
Temporal cortexd
5.73 (0.78)
Parahippocampal gyrus
3.83 (0.50)
Temporal poled
4.52 (0.59)
Entorhinal
3.16 (0.42)
Cingulate
Anterior cingulate
6.08 (0.83)
Posterior cingulate
5.34 (0.69)
Isthmus cingulate
4.35 (0.67)
Insula
5.12 (0.66)
Subcortical regionsd
3.40 (0.33)
Thalamus
2.58 (0.25)
Amygdalad
3.94 (0.40)
Hippocampus
2.74 (0.37)
Striatum
4.75 (0.49)
Putamen
5.40 (0.53)
Caudate
4.09 (0.54)
Pallidum
2.13 (0.28)
Cerebellum cortex
2.89 (0.43)
Abbreviation: BPND, binding potential.
a

Cohen’s d

% difference

3.83 (0.73)

-12.5%

4.16 (0.78)
5.03 (1.03)
5.09 (1.16)
4.81 (1.20)
4.01 (1.01)
5.56 (1.25)
4.69 (1.13)
5.30 (1.33)
5.38 (1.15)
4.88 (1.04)
5.07 (1.06)
4.28 (1.01)
5.24 (1.07)
3.28 (0.72)
3.86 (1.04)
3.09 (0.72)

-8.9%
-9.9%
-12.3%
-14.9%
-16.3%
-13.8%
-18.8%
-16.5%
-15.7%
-15.6%
-17.4%
-19.2%
-8.5%
-14.3%
-14.6%
-2.1%

.18
.16
.07
.04
.03
.06
.01
.04
.03
.03
.02
.01
.22
.04
.08
.79

5.29 (1.30)
4.68 (0.94)
3.80 (0.80)
4.49 (0.87)
3.11 (0.50)
2.27 (0.39)
3.74 (0.62)
2.44 (0.44)
4.13 (0.70)
4.99 (0.75)
3.27 (0.77)
2.28 (0.38)
2.58 (0.58)

-13.0%
-12.4%
-12.5%
-12.2%
-8.5%
-12.0%
-5.1%
-11.1%
-12.9%
-7.5%
-20.0%
+7.3%
-10.9%

.09
.06
.08
.06
.12
.03
.36
.07
.02
.14
.006
.26
.14

0.93

P values are for 2-tailed, unpaired t tests.
These analyses were exploratory and not corrected for multiple comparisons due to the
preliminary nature of the study.
c n = 10 for the HIV group.
d n = 11 for the HIV group.
b

P valuea

HIV (n = 12)

.04
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Table 5: SV2A PET Synaptic Density (BPND) in Brain Regions of Interest (1TC
Weighted Averages)
BPND
Mean (SD)
HIV-uninfected
participants
(n = 13)

Region of Interest
Primary region
Frontostriatalthalamicb
5.46 (0.55)
Secondary regionsc
Whole grayb,d
5.15 (0.62)
Cortical regionsb,d
5.91 (0.73)
Frontal cortex
5.81 (0.61)
Superior frontal gyrus
5.65 (0.61)
Paracentral lobule
4.79 (0.61)
Parietal cortexb,e
6.45 (0.87)
Postcentral gyrus
5.77 (0.70)
Superior parietal lobuleb,e
6.34 (0.80)
Precuneusb,e
6.38 (0.84)
Occipital cortexb,e
5.79 (0.83)
Cuneusb,e
6.14 (0.92)
Lingual gyrus
5.30 (0.82)
Temporal cortexb,e
5.73 (0.78)
Parahippocampal gyrus
3.83 (0.50)
Temporal poleb,e
4.52 (0.59)
Entorhinal
3.16 (0.42)
Cingulate
Anterior cingulate
6.08 (0.83)
Posterior cingulate
5.34 (0.69)
Isthmus cingulate
4.35 (0.67)
Insula
5.12 (0.66)
Subcortical regionsb,e
3.06 (0.38)
Thalamus
2.58 (0.25)
Amygdalae
3.94 (0.40)
Hippocampus
2.74 (0.37)
Striatumb
4.84 (0.50)
Putamen
5.40 (0.53)
Caudate
4.09 (0.54)
Pallidum
2.13 (0.28)
Cerebellum cortex
2.89 (0.43)
Abbreviation: BPND, binding potential.
a

Cohen’s d

% difference

4.79 (1.04)

-12.3%

4.48 (0.97)
5.11 (1.14)
5.09 (1.16)
4.81 (1.20)
4.01 (1.01)
5.56 (1.25)
4.69 (1.13)
5.30 (1.33)
5.38 (1.15)
4.88 (1.04)
5.07 (1.06)
4.28 (1.01)
5.24 (1.07)
3.28 (0.72)
3.86 (1.04)
3.09 (0.72)

-13.1%
-13.6%
-12.3%
-14.9%
-16.3%
-13.8%
-18.8%
-16.5%
-15.7%
-15.6%
-17.4%
-19.2%
-8.5%
-14.3%
-14.6%
-2.1%

.055
.051
.07
.04
.03
.06
.01
.04
.03
.03
.02
.01
.22
.04
.08
.79

5.29 (1.30)
4.68 (0.94)
3.80 (0.80)
4.49 (0.87)
2.74 (0.54)
2.27 (0.39)
3.74 (0.62)
2.44 (0.44)
4.23 (0.74)
4.99 (0.75)
3.27 (0.77)
2.28 (0.38)
2.58 (0.58)

-13.0%
-12.4%
-12.5%
-12.2%
-10.7%
-12.0%
-5.1%
-11.1%
-12.7%
-7.5%
-20.0%
+7.3%
-10.9%

.09
.06
.08
.06
.10
.03
.36
.07
.03
.14
.006
.26
.14

0.81

P values are for 2-tailed, unpaired t tests.
BPND for these composite regions were calculated using a volume-based weighted average of
the constituent regions.
c These analyses were exploratory and not corrected for multiple comparisons due to the
preliminary nature of the study.
d n = 10 for the HIV group.
e n = 11 for the HIV group.
b

P valuea

HIV (n = 12)

.06
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Table 6: Multivariable Regression Model of
Frontostriatalthalamic Synaptic Density and HIV Statusa

Parameters
HIV
Age

(R2 = 0.27, P = .03)b
Frontostriatalthalamic BPND
β-estimate
P-value
0.13
.03
0.02
.21

Parameters
HIV
Education

(R2 = 0.22, P = .07)b
Frontostriatalthalamic BPND
β-estimate
P-value
0.15
.03
0.07
.95

Parameters
HIV
Race

(R2 = 0.22, P = .06)b
Frontostriatalthalamic BPND
β-estimate
P-value
0.15
.03
0.15
.89

Parameters
HIV
Age
Education
Race

(R2 = 0.27, P = .19)b
Frontostriatalthalamic BPND
β-estimate
P-value
0.17
.08
0.03
.32
0.08
.61
0.18
.95

a

Least squares multivariable regression model to evaluate the relationship
between frontostriatalthalamic BPND and HIV status, with adjustment for
potential confounders.
b R2 represents the coefficient of determination and the proportion of
variance explained by the model. P-value represents significance by the
whole model ANOVA test.
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Table 7: FreeSurfer MRI Volume Measures in Brain Regions of Interest
Volume (mL)
Mean (SD)
HIV-uninfected
participants
(n = 13)

Region of Interest
Primary regions
Frontostriatalthalamic
184.96 (19.06)
Secondary regionsb
Whole brainc
36.11 (2.90)
Cortical regionsc
435.12 (42.97)
Frontal cortex
153.16 (16.98)
Superior frontal gyrus
40.28 (4.40)
Paracentral lobule
7.43 (0.81)
Parietal cortexd
102.07 (10.43)
Postcentral gyrus
17.42 (1.76)
Superior parietal lobuled
24.05 (2.93)
Precuneusd
19.29 (2.58)
Occipital cortexd
48.47 (5.34)
Cuneusd
6.73 (0.96)
Lingual gyrus
13.77 (2.12)
Temporal cortexd
94.74 (9.81)
Parahippocampal gyrus
3.90 (0.37)
Temporal poled
4.46 (0.69)
Entorhinal
4.30 (0.76)
Cingulate
Anterior cingulate
7.14 (0.89)
Posterior cingulate
10.83 (1.56)
Isthmus cingulate
5.11 (0.91)
Insula
13.60 (1.77)
Subcortical regionsd
22.25 (1.59)
Thalamus
14.89 (2.01)
Amygdalad
3.31 (0.33)
Hippocampus
8.44 (0.63)
Striatum
16.91 (1.27)
Putamen
9.72 (0.84)
Caudate
7.19 (0.65)
Pallidum
4.07 (0.51)
Brain stem
12.67 (1.44)
Pons
10.39 (1.39)
Cerebellum cortex
108.13 (8.90)
Abbreviation: BPND, binding potential.
a

HIV
(n = 13)

% difference

P valuea

179.69 (15.01)

-2.9%

.44

34.59 (3.16)
416.49 (40.53)
149.05 (12.77)
38.40 (3.89)
7.42 (1.08)
97.11 (10.33)
15.62 (1.80)
23.38 (2.53)
18.72 (2.28)
44.76 (6.44)
6.18 (0.97)
13.23 (2.44)
89.93 (9.04)
3.90 (0.67)
4.28 (0.63)
3.88 (0.68)

-4.3%
-4.2%
-2.7%
-4.7%
-2.2%
-4.9%
-10.3%
-2.8%
-2.9%
-7.7%
-8.2%
-3.9%
-5.1%
+0.0%
-4.1%
-9.8%

.24
.29
.49
.26
.97
.24
.02
.54
.57
.13
.17
.55
.22
1.00
.50
.15

7.55 (0.89)
10.81 (1.53)
4.80 (0.96)
13.79 (1.52)
21.38 (1.98)
14.16 (2.02)
3.35 (0.53)
8.04 (0.92)
16.48 (2.00)
9.28 (1.17)
7.20 (1.16)
3.83 (0.50)
12.14 (1.50)
10.24 (1.25)
103.56 (10.24)

5.7%
-0.0%
-6.1%
1.4%
-3.9%
-4.9%
+1.3%
-4.8%
-2.6%
-4.6%
+0.2%
-5.8%
-4.2%
-1.4%
-4.2%

.25
.97
.41
.77
.24
.36
.82
.21
.52
.28
.97
.25
.37
.78
.24

P values are for 2-tailed, unpaired t tests.
These analyses were exploratory and not corrected for multiple comparisons due to the
preliminary nature of the study.
c n = 11.
d n = 12.
b
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Group Differences in Synaptic Density in Secondary HIV-Related Brain
Regions and Whole Brain
Exploratory analyses of additional ROIs that have previously been
implicated in neurological impairment in PLWH were performed as well.
Widespread differences in synaptic density in HIV participants as compared to
HIV-uninfected participants were observed, most notably in cortical regions
(Figure 5, Table 2), despite similar volumes (Table 7). The only ROI
demonstrating a significant group difference in volume was the postcentral gyrus
(15.62 [1.80], 17.42 [1.76]; P = .02). These comparisons were not corrected for
multiple comparisons due to the exploratory nature of these analyses in the pilot
study. These results were also largely unchanged when using 1TC-derived BPND
and/or using a weighted average to calculate frontostriatalthalamic BPND (Tables
3-5). All but one brain region exhibited lower BPND after partial volume correction
in HIV participants (percent difference range: 4-22%). When examining
composite brain regions, we found significantly lower synaptic density in cortical
(14.9% lower), subcortical (11.5% lower), and whole gray (13.7% lower)
composites (Figure 6).
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Figure 5: Regional mean SV2A binding potential (BPND) after partial volume correction. In
all individual secondary regions of interest by HIV status. * P < .05. Error bars represent 95%
confidence intervals. This figure shows exploratory analyses that were not corrected for multiple
comparisons.

Figure 6: Composite mean SV2A binding potential (BPND) after partial volume correction. In
composite whole gray matter, cortical, and subcortical regions. Error bars represent 95%
confidence intervals. Individual data points are shown for all participants in both groups.

Among cortical regions, there was significantly lower synaptic density in
HIV participants in the parietal (5.54 [1.49], 6.77 [0.90]; P = .02), occipital (4.94
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[1.16], 6.04 [0.83]; P = .01), and frontal (5.22 [1.28], 6.08 [0.67]; P = .045)
cortices. In addition, there was a trend toward lower synaptic density in the
temporal cortex among HIV participants (5.30 [1.09], 6.00 [0.79]; P = .07). Within
the temporal cortex, we observed significantly lower BPND in the
parahippocampal gyrus and temporal pole. Other cortical regions with
significantly lower BPND include the insula and posterior cingulate. There was
also a trend toward lower synaptic density in both the anterior (5.48 [1.39], 6.41
[0.89]; P = .053) and isthmus (3.94 [0.91], 4.55 [0.68]; P = .06) cingulate.
Subcortical regions with lower BPND in HIV participants included the thalamus,
hippocampus, striatum, and caudate. Figure 7 illustrates regional and
widespread differences in synaptic density in PLWH compared to HIV-uninfected
participants using mean group parametric images of BPND values. Decreased
synaptic density can be seen across many brain regions.
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Figure 7: Averaged group SV2A binding potential (BPND) parametric images. The whole
brain is shown in averaged group SV2A binding potential (BPND) parametric images for HIVuninfected participants (left) and HIV (middle) participants. Magnetic resonance imaging template
(right) for reference. Color scale denotes BPND.

Associations between Synaptic Density and Neurocognitive Function in
PLWH
Relative to normative population data, PLWH performed below average in
all but two of the 18 neurocognitive tests, including eight tests in which
performance was at least one standard deviation below average (Table 8). A
global average of z-scores for all tests was calculated for each participant. The
mean global average z-score for our sample was one standard deviation below
the normative average (-1.0 [0.8]), indicating impairment in this group.
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Table 8: Neuropsychological Test Scores for HIV Participants
z scorea
Median (IQR)
Neuropsychological test
HIV (n = 13)
Timed Gait
-1.2 (-2.3, 0.4)
WRAT-4
-0.9 (-1.8, 0.0)
HVLT-R Total Recall
-0.3 (-1.3, 0.2)
HVLT-R Delayed Recall
-1.0 (-2.3, -0.4)
HVLT-R Retention
-1.3 (-2.7, 0.6)
HVLT-R Recognition Discrimination Index
-1.3 (-2.8, -0.5)
Trail Making A
-0.7 (-2.5, -0.1)
Trail Making B
-0.9 (-3.0, -0.2)
Grooved Pegboard (dominant)
-1.0 (-3.6, 0.0)
Grooved Pegboard (non-dominant)
-1.5 (-4.5, -0.1)
WAIS-III Digit Symbol
-0.5 (-1.4, 0.5)
Stroop Color Naming
-1.6 (-2.7, -0.3)
Stroop Word Reading
-1.8 (-3.4, -1.1)
Stroop Interference
-0.2 (-0.8, 0.3)
Letter Fluency
-0.5 (-1.4, 0.8)
Category Fluency
-0.8 (-1.0, 0.9)
Finger Tapper (dominant)
0.3 (-0.5, 0.9)
Finger Tapper (non-dominant)
0.1 (-0.8, 1.1)
Mean (SD)
Global Average
-1.0 (0.8)
Abbreviations: HVLT-R, Hopkins Verbal Learning Test – Revised; IQR, Interquartile range; WAIS,
Wechsler Adult Intelligence Scale; WRAT, Wide Range Achievement Test.
a z score values are in relation to normative data

We assessed for correlations between synaptic density in the
frontostriatalthalamic circuit and neurocognitive performance in HIV participants
(Figure 8). Significant associations were observed between grooved pegboard
performance, a measure of motor and executive function, and
frontostriatalthalamic BPND (non-dominant: r = 0.61, P = .03; dominant: r = 0.54,
P = .06). Better performance on the grooved pegboard was also associated with
greater hippocampal BPND (non-dominant: r = 0.60, P = .03; dominant: r = 0.59, P
= .03) and a trend toward greater subcortical BPND (non-dominant: r = 0.52, P =
.07; dominant: r = 0.43, P = .14). There was a trend toward a significant
association between Trail Making Test Part A (TMTA) performance, a measure
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of processing speed, and frontostriatalthalamic (r = 0.54, P = .06) and
hippocampal (r = 0.51, P = .08) BPND.

Figure 8: Association between frontostriatalthalamic BPND and neuropsychological test
scores. Correlations were computed using Pearson’s r.

Associations between Synaptic Density and Demographic and Clinical
Measures in PLWH
We next sought to assess whether there were any relationships between
synaptic density in the HIV group and other measured variables. We performed a
correlation analysis between frontostriatalthalamic synaptic density and the
demographic and clinical measures reported in Table 1, finding no significant
associations among HIV participants. Notable variables that were not associated
with frontostriatalthalamic BPND included age (r = 0.17, P = .59), years of
education (r = 0.07, P = .83), CD4 T-cell count (r = 0.35, P = .25), CD4 nadir (r =
0.09, P = .82), plasma HIV viral load (not detected: 3.80 [0.61]; detected: 4.15
[1.09]; P = .54), CSF HIV viral load (not detected: 3.80 [0.77]; detected: 4.09
[0.99]; P = .61), duration of HIV infection (r = 0.07, P = .82), and history of SUD
(no SUD: 3.91 [0.50]; SUD: 3.94 [0.98]; P = .95).
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Associations between Neuropsychologic Testing and HIV-Specific Clinical
Measures in PLWH
To assess for associations between NPT and HIV-specific clinical
measures in PLWH, we performed a correlation analysis between z-scores for
the NPTs and the following selected HIV-specific variables: CD4 nadir, CD4 Tcell count, CD4/CD8 ratio, plasma and CSF viral loads, CSF white blood cells
(WBCs), CSF protein, and duration of HIV. Higher current CD4 T-cell count was
associated with better performance on the WAIS-III Digit Symbol (r = 0.64, P =
.02) and Stroop color naming tests (r = 0.58, P = .046). Similar, albeit not
significant, trends were seen with the Stroop word reading (P = .06) and TMTA
(P = .07) tests. Increased CSF WBC count had associations with worse
performance on the letter fluency (r = 0.69, P = .01) and finger tapping tests (r =
0.59, P = .046). We also observed a non-significant trend toward worse
performance on the WRAT-4 with higher CSF WBCs (P = .07). There was also
an association between longer duration of HIV infection and worse performance
on the HVLT-R total recall test (r = 0.62, P = .02). There were no significant
associations between neurocognitive performance and CD4 nadir, CD4/CD8
ratio, plasma HIV viral load, CSF HIV viral load, or CSF protein. However, there
was a trend toward worse performance on the TMTA (P = .08), WAIS-III Digit
Symbol (P = .08), Stroop color naming (P = .09), and dominant finger tapping (P
= .08) tests with lower CD4 nadir.
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DISCUSSION
In this pilot study, we evaluated synaptic density in PLWH using in vivo
SV2A PET imaging. Until now, assessment of synaptic density in HIV has been
limited to investigations using postmortem brain tissue. To our knowledge, this is
the first study to provide in vivo evidence of significantly lower synaptic density in
PLWH in the frontostriatalthalamic circuit, an area consistently implicated in
neuropathological studies and both structural and functional MRI studies of
neurocognitive dysfunction in PLWH. Exploratory analyses, uncorrected for
multiple comparisons, hint at more widespread loss of synaptic density in PLWH.
Further, in this small study, lower frontostriatalthalamic BPND was associated with
poorer performance on a standardized measure of motor and executive function.
This study provides compelling initial evidence that SV2A PET imaging as a
research modality can measure in vivo differences in synaptic density in PLWH.
Findings of this study provide additional evidence that the frontostriatalthalamic
circuit may be implicated in the neuropathology of HIV.
While SV2A PET imaging is a recent development, it has already been
used to study synaptic density in Alzheimer’s disease,100 depression,104 PTSD,104
Parkinson disease,103 schizophrenia,101 and epilepsy.102 Among other notable
findings, one study found large reductions in synaptic density in the seizure onset
zone (SOZ) relative to the contralateral side, providing a biomarker for accurately
identifying the SOZ in the presurgical evaluation of these patients. In Parkinson
disease, lower synaptic density was observed at earlier stages of Parkinson
disease than previously known. Collectively, these studies have led to novel
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insights in our understanding of the pathogenesis of these disorders, allowing for
subtle changes to be detected in such early-stage brain injuries, and have
already demonstrated utility as biomarkers for treatment monitoring and disease
progression. Notable associations with cognitive function testing have been
identified in these studies as well. In the current study, we applied this tool to
identify synaptic density as a potential biomarker associated with neurocognitive
impairment in PLWH.
The etiology of CNS dysfunction in people with well-treated HIV is likely
multifactorial.117 Contributing factors for CNS dysfunction in PLWH include legacy
effects from CNS damage during initial HIV infection,96 ongoing
neuroinflammation and immune activation,74 ART toxicities,118 HIV escape and
persistence,119 lifestyle factors, non-infectious comorbidities,120 accelerated
aging,121 and mental health disorders. A challenge to better understanding
neurocognitive impairment in HIV is determining to what extent disease-related
factors versus common key confounders in PLWH (i.e., mood disorders,
polypharmacy, substance use)122 contribute to brain injury.123 Further, both HIV
and these comorbid conditions may affect cognition separately from any direct
synaptodendritic injury they may cause. This has been particularly difficult due to
the absence of a sensitive measure of brain pathology.
Synaptodendritic injury, a known feature of neurocognitive dysfunction in
PLWH, is associated with severity of cognitive injury, with some studies
indicating this correlation is stronger than other classic pathologic markers of HIV
encephalitis, such as microglial nodules and multinucleated giant cells.49,124
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There are several proposed mechanisms of synaptic degeneration in HIV,
including an inflammatory milieu generated by proliferating immune cells, toxic
impact of viral proteins, viral replication, and exposure to methamphetamines and
opiates.49,61,65,66,125 Understanding of synaptodendritic injury and other
pathological changes in the brain during HIV infection has been limited by lack of
appropriate research modalities.
In this study, we found a large magnitude reduction in synaptic density in
PLWH after correction for cerebral atrophy despite long-term ART compared with
age-matched HIV-uninfected participants. Lower synaptic density in the
frontostriatalthalamic pathway is consistent with findings of atrophy in structural
MRI studies of PLWH53,54 as well as functional MRI studies demonstrating
compromised connectivity in this circuit and associations with cognitive
impairment.55-57 This was detected despite the relatively small sample, and
withstood correction for age and brain atrophy, indicating the potential for SV2A
PET imaging as a useful marker of synaptic density in PLWH.
While synaptic density was significantly lower in PLWH in our study, it is
notable that this reduction is relatively modest in comparison to findings from
other SV2A PET studies in different diseases despite similar sample sizes. In
mild to moderate Alzheimer disease there was a 41% decrease in hippocampal
synaptic density compared to healthy controls;100 in Parkinson disease a 45%
reduction in synaptic density in the substantia nigra was observed.103 However,
these diseases have established anatomical pathological correlates. Further,
reductions in synaptic density were highly regional in other SV2A PET studies,
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whereas our results indicate a more global effect on the brain with some areas
affected slightly more than others. This may reflect the highly multifactorial nature
of neurocognitive dysfunction in PLWH, with numerous factors contributing to
functional impairment and synaptodendritic injury.
In addition to the reduced density in the frontostriatalthalamic circuit, we
observed more global reductions in both cortical and even some subcortical
areas, a finding that is unique compared to SV2A PET studies in other disease
states. While MRI studies as a whole have most consistently found atrophy and
disrupted connectivity in specific areas of the brain, the literature is rife with
findings involving many brain regions. Further, cognitive deficits seen in HIVassociated neurocognitive disorder span several domains and thus do not
cohesively implicate any particular part of the brain. Therefore, it is not especially
surprising that we detected small but significant widespread reductions in
synaptic density. While it is possible that this simply reflects the small sample
size or imperfect matching, it may imply superior sensitivity of this modality in
detecting subtle changes in the brains of PLWH. If this finding holds, it has the
potential to shift our understanding of brain injury in PLWH from one focused on
regions and functional circuits with well-known correlates to a more global view.
Notably, this modality demonstrated differences in synaptic density that
were not detected by the volumetric analysis. This may imply that decreased
synaptic density is more sensitive than brain atrophy in identifying brain injury in
HIV. One possible explanation for this finding is that it reflects more marked
synaptodendritic injury, but only mild neuronal loss. Given that direct neuronal
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damage (and thus brain atrophy) is thought to occur primarily during acute HIV
infection prior to ART,126 whereas synaptodendritic injury may continue in welltreated chronic HIV, these findings may reflect the lengthy mean duration of HIV
infection, but long-term viremic suppression, in our cohort.
Furthermore, even in this small pilot study a significant association was
observed between synaptic density in the frontostriatalthalamic circuit and
performance on the grooved pegboard test, a measure of motor integration and
executive function.127 Frontostriatal circuits, along with their connections to the
thalamus, are known to mediate motor and oculomotor function,128 both of which
are important in the grooved pegboard test. In HIV, there is evidence that basal
ganglia gray matter (i.e., striatum) atrophy is associated with motor
dysfunction.129 There is further evidence of the association between abnormal
frontostriatal connectivity and motor and executive dysfunction from studies in
Parkinson disease and schizophrenia.130-132 There was also a strong trend
pointing towards an association with performance on the TMTA. TMTA is widely
used as a measure of cognitive processing speed and executive functioning, two
domains that are frequently affected in PLWH. Studies have found poorer
performance in TMTA among PLWH, and TMTA performance has structural
correlates to the frontal cortex and striatum.133,134
Interestingly, frontostriatalthalamic synaptic density did not correlate with
performance on other NPTs, despite the cohort’s widespread abnormal
performance on our battery. Out of all the tests in the battery, grooved pegboard
and TMTA performance may be most strongly related to frontostriatalthalamic
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functioning, partially explaining why other associations were not observed. Other
factors, including the small sample size and expected variations in test
performance, also likely contributed to this finding. Nevertheless, the finding that
this modality associates with cognitive testing is particularly promising, even in a
small sample, given the lack of any existing biomarkers or other measures that
consistently correlate with neurocognitive disorders in PLWH.
In this study we did not find any significant associations between
frontostriatalthalamic synaptic density and any demographic or clinical measures
among PLWH. Although this may well be due to the small sample size, it
potentially provides further evidence for synaptic density being a unique
biomarker, independent of routine clinical or demographic confounders.
However, it is important to note that we did not assess markers of
neuroinflammation or immune activation, which may have significant associations
with synaptic density. This is of particular importance since volumetric studies
have found associations between brain atrophy and levels of various metabolites,
cytokines (i.e., sCD14, IP-10), and other markers of brain injury and immune
activation (i.e., S100B, neopterin), both in the plasma and CSF.54,135-138
In exploratory analyses, we found several associations between clinical
HIV measures and NPT performance. While higher CD4 T-cell count correlated
with performance on several tests, it is difficult to draw any conclusions from
these findings given the small sample size and multiple studies establishing that
current HIV viral load and CD4 count are not closely associated with impairment
in the ART era.139,140 However, associations between increased CSF WBC count
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and poor performance on letter fluency, finger tapping, and WRAT-4 tests in our
study are notable as prior studies have found a correlation between CSF
pleocytosis, CSF viral escape, and neurocognitive impairment.141 While we did
not find significant associations between NPT performance and CD4 nadir, there
were a number of trends toward worse performance with lower CD4 nadir,
consistent with the well-established relationship between CD4 nadir and
cognitive impairment in PLWH.92 Since our small sample was further reduced in
this particular analysis (CD4 nadir was only available for nine participants), we
would expect that the observed trends between CD4 nadir and NPT would reach
significance, and associations with other tests may emerge too, with a larger
sample.
Future Directions
Results of this initial study highlight the need for future investigations. Our
ongoing longitudinal SV2A study, which will measure synaptic density over 24
months in a larger group of PLWH on ART relative to a matched prospectively
enrolled HIV-uninfected group, will further elucidate interactions between
synaptic loss due to aging with loss due to HIV, including a potential accelerated
loss of synaptic density in adults aging with HIV.142 Furthermore, combining
longitudinal SV2A imaging of synaptic density with PET imaging of neuroimmune
status (using the radioligand [11C]PBR28 targeting the 18-kDa translocator
protein, or TSPO, which is sensitive to microglia) and cerebrospinal fluid
measures of immune activation will determine the extent to which
neuroinflammation impacts synaptic density and neurocognitive function. The
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successful use of SV2A PET imaging in HIV raises the possibility that it could
also be useful in elucidating the etiology of CNS injury and cognitive impairment
in other acute and chronic viral infections that impact the brain, such as COVID19 and varicella zoster virus (VZV). COVID-19 in particular has received
significant attention given the frequency with which infected individuals develop
neurological symptoms, with studies now strongly implicating neuroinflammation
playing a role.143,144 In addition, there is some preliminary evidence identifying
structural gray matter perturbations using multimodal brain imaging in people
with prior COVID-19 infection.145
In addition, specific MRI sequences were obtained in the current study
that will allow us to perform diffusion tensor imaging (DTI) and neurite orientation
dispersion and density imaging (NODDI) analyses using the existing data. These
ongoing analyses will provide information on white matter tractography and cellspecific integrity (e.g., in dendrites and axons), respectively, and whether there
are associations with SV2A measures.
Limitations
This pilot study was designed to detect overall group differences between
PLWH and age- and sex-matched historical controls; larger studies with
prospectively enrolled controls matched for additional clinical and demographic
factors are needed to determine the contribution of HIV disease versus
comorbidities in PLWH to our findings. This study’s power was further limited
because of the COVID-19 pandemic, causing participant recruitment to be
stopped prematurely. There was a significant difference in the racial composition
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of the two groups, however, we have no plausible biological reason to expect a
difference in synaptic density due to race alone, and the group difference
remained significant when race was used as a covariate. Further,
frontostriatalthalamic BPND was not associated with race in our cohort, and there
is no published evidence that synaptic density in HIV is associated with race, nor
have there been studies showing a relationship between synaptic density and
race more generally. Drug abuse is known to cause synaptodendritic changes,
and while we found no associations between synaptic density and history of
substance or alcohol abuse among HIV participants, we were not able to account
for these variables in our comparative analyses as this data was not available for
the HIV-uninfected group.
Similarly, studies with larger samples are needed to further investigate
associations between synaptic density and neurocognitive performance, as well
as associations with other HIV-associated lab and clinical parameters, such as
CD4 nadir and duration of HIV infection, which were not observed in this small
study. Finally, our sample was older and entirely male, limiting generalizability.
While a homogeneous cohort is an advantage for this analysis given the small
sample size, future studies should focus on recruiting more diverse samples,
including women and younger individuals, as HIV-sex and HIV-age interactions
may affect synaptic density in these populations.106
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CONCLUSIONS
We used novel PET imaging of SV2A to assess synaptic density in a
cohort of older male, virologically suppressed HIV participants and
demographically similar HIV-uninfected participants, demonstrating lower
synaptic density in the frontostriatalthalamic circuit, among other brain regions, in
the HIV group. The detection of synaptodendritic injury independent of brain
atrophy in PLWH with viral suppression, in association with reduced
neurocognitive function, suggests a potentially reversible neuropathology in
some PLWH. These pilot observations raise questions regarding the etiology of
the differences observed between the two groups, which need to be determined
in larger studies examining mechanisms underlying synaptic density in diverse
populations of PLWH. This method provides promise as a valuable in vivo
molecular biomarker of CNS dysfunction in HIV, which may affect up to half of
the 38 million PLWH worldwide, as well as an outcome measure for trials of
disease-modifying therapies in this population.
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